• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Review of Proposed Proprietary Name - May 19, 2009 - Hiberix

Department of Health and Human Services

Public Health Service

Food and Drug Administration

Center for Biologics Evaluation and Research

MEMORANDUM

Date:May 19, 2009
From:

Maryann Gallagher, Consumer Safety Officer

OCBQ/DCM/APLB, HFM-602

Through:

Ele Ibarra-Pratt, RN, MPH, Branch Chief 

OCBQ/DCM/APLB, HFM-602

Through:

Robert A. Sausville, Division Director

OCBQ/DCM, HFM-610

To:

Jason Humbert, RPM, OVRR/DVRPA/CMC (HFM-481)

Jay Slater, M. D., Committee Chair, OVRR/DDBPAP (HFM-422)

Karen Farizo, M. D., Clinical Reviewer, OVRR/DVRPA/CRB1 (HFM-475)

Subject:

Review of Proposed Proprietary Name HIBERIX

[Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)]

BLA STN: 125347

Sponsor: Glaxo SmithKline

Recommendation:       Acceptable with Concerns


Executive Summary:

APLB recommends that the proposed proprietary name, HIBERIX, [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)], be found Acceptable with Concerns

Background:

On March 17, 2009  Glaxo SmithKline (GSK) submitted BLA STN 125347 for Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate).

On March 31, 2009, the sponsor submitted a request for a review of the proposed proprietary name, HIBERIX, for review.

The PDUFA action date for the BLA for HIBERIX is August 1, 2009.

HIBERIX is a trademark developed by GlaxoSmithKline.  The name HIBERIX represents components of the vaccine (Hib- for Haemophilus influenzae type b) combined with –rix which is commonly used by GlaxoSmithKline’s vaccine portfolio trademarks.  HIBERIX is currently licensed in 98 countries worldwide and there have been no reports of safety concerns.

HIBERIX is proposed for active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib) in children 15 months through 4 years of age (prior to fifth birthday).  The booster dose is critical in boosting antibody titers and ensuring continued protection.

HIBERIX has the potential to provide an additional source of monovalent Hib vaccine to the US market for the booster dose in the current shortage to avoid break-through Hib disease.

There are currently two licensed Haemophilus influenzae type b vaccine products:

ActHIB, Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) vaccine combined with Sanofi Pasteur Inc. DTP vaccine by reconstitution is indicated for the active immunization of infants and children 2 through 18 months of age for the prevention of invasive disease caused by H influenzae type b and/or diphtheria, tetanus and pertussis. 

PedvaxHIB, Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age. Merck suspended production and the distribution is not expected before mid-2009.

GSK submitted the results of a study conducted by the --------b(4)---------------------, a subsidiary of ----b(4)------------------ conducted a Proprietary Name Analysis and a Proprietary Name Promotional Assessment which was completed in March 2009. -b(4)- concluded that when HIBERIX is compared to other product names, seven names were identified as potentially similar to Hiberix (e.g., Havrix, Hexabrix, Hibiclens, Hiprex, Iferex 150, Imitrex, and Niferex).  Based on the –b(4)- analysis, no names were considered an apparent issue for the prescribing/ dispensing of HIBERIX.  The Proprietary Name Promotional Assessment confirmed that HIBERIX is not promotional or misleading.  APLB reviewed the -b(4)- report, which was included in the sponsor’s request for a proprietary name review.

Overview of the Proposed Indication, Dosage Form, Dose, Administration, and Storage Information:

HIBERIX will be indicated for active immunizations as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib) for use in children 15 months through 4 years of age (prior to fifth birthday).

HIBERIX is a sterile, lyophilized powder which is reconstituted at the time of use with the accompanying saline diluent.  Each vial of lyophilized vaccine injection will contain 10 mcg of purified capsular polysaccharide (PRP) covalently bound to approximately 25 mcg tetanus toxoid (TT) and 12.6 lactose as a stabilizer to be reconstituted with the accompanying saline diluent supplied in prefilled syringes.  HIBERIX 0.5 mL will be administered via intramuscular injection after reconstitution.

The lyophilized vaccine vials require refrigeration at temperatures between 2° and 8° C (35° and 46° F) and protected from light. The diluent requires refrigeration between 2° and 8° C (35° and 46° F) or at a controlled room temperature between 20° and 25° C (68° and77° F) and should be discarded if frozen. The reconstituted product should be stored between -------b(4)------------

-b(4)- and should be used within 24 hours of reconstitution.  HIBERIX should be discarded if frozen.

–b(4)- conducted a safety study with 150 healthcare professionals and identified eight proprietary names, Clarinex, Havrix, Heparin, Herplex, Hiprex, histineex HC, Imitrex, and Pediarix as having sound–alike, look-alike characteristics with HIBERIX.  The –b(4)- Safety Evaluators. assessed the product profiles of these names compared to that of HIBERIX, and concluded that minimal overlapping drug profile characteristics were identified that would contribute to a medication error.

APLB completed an independent review of existing proprietary and established/proper names.

  1. False or Misleading [21 U.S.C. section 321(n)]:

The proposed proprietary name, HIBERIX, is not regarded to be false or misleading.

  1. Fanciful [21CFR 201.10 (c)(3)]:

The proposed proprietary name, HIBERIX, is not regarded to be fanciful.

  1. Similarity in Spelling or Pronunciation [21 CFR 201.10 (c) (5)]:

HIBERIX may be confused with the proprietary names for other marketed products of similarity in spelling or pronunciation.  Since drug products are prescribed through written, verbal, and /or electronic orders, similarity in spelling or pronunciation via such forms of communication may lead to medication errors. Even when proprietary names are only slightly similar, overlapping product characteristics may contribute to a greater potential for confusion.

APLB acknowledges that there is a minimal potential for medication error due to similarity in spelling and pronunciation between HIBERIX and other marketed products.  Some of the marketed products whose names share many phonetic and orthographic similarities to HIBERIX include Havrix, Hexabrix, Hiprex, and Imitrex.

There is a slight potential for confusion with other GSK vaccines because they end in "rix": Boostrix, Fluarix, Engerix B, Havrix, Infanrix, Twinrix, Pediarix, and Kinrix but the beginnings of their proprietary names are not similar to HIBERIX.

APLB also considers the following risk factors to evaluate the degree to which HIBERIX may be of concern for medication errors:

Strength/Dose/Dosage Form/Route of Administration

Indications and/or Pharmacological-Therapeutic Categories

Marketing Status (prescription – RX or over-the-counter – OTC)

Storage Location (room temperature or refrigerator)

Products are listed in the table below from the highest to lowest potential for causing a medication error.

Proprietary name (established/ proper name)Dosage FormDose & AdministrationIndicationRX/OTCStoragePotential for medication error

HIBERIX

[Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)]

IM injection (lyophilized vaccine vial with saline diluent in prefilled syringe

Single 0.5  mL dose IMActive immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib) in children 15 months through 4 years of age.RXLyophilized vials refrigerator and protect from lightN/A

Havrix

Hepatitis A Virus Vaccine

 

Suspension for IM injection in vials & syringes

Children & Adolescents 0.5mL and 0.5 mL booster dose administered between 6 & 12 months later.

Adults: 1 mL dose and 1mL booster dose between 6 & 12 months later.

Active immunization against hepatitis A for persons      ≥ 12 months of age.RXRefrigeratorModerate
Hexabrix ioxaglate meglumine and ioxaglate sodium

Solution for IV injection

5-15 mLPediatric angiocardiography; arteriography; angiography; venography; urography; arthrography; hysterogramRXBelow 30°C (86) Do not freezelow
Imitrex sumatriptan succinate

Subcutaneous injection

Tablet

Intranasal spray

Injection 6 mg/day;

oral 25-200mg/day

nasal 5-40 mg/day

treatment of migraine attacks with or without aura and 2) cluster headachesRX

Refrigerator and protect from light

 

low
Hiprex methenamine hippurate

tablet

1 g twice dailyUrinary tract infections prophylaxisRXRoom temperaturelow

When the product profiles of the above products were compared to that of HIBERIX, overlapping characteristics were identified that were regarded as an issue for prescribing/ dispensing of HIBERIX.

Havrix and HIBERIX have a similar sound alike and look-alike characteristics and overlapping product characteristics.  Both products are IM injectable products and are stored in the refrigerator.  Both products are indicated as immunization for children, HIBERIX for haemophilus vaccine in children 15 months through 4 years of age and Havrix for hepatitis for hepatitis A for persons 12 months of age and older.  There is a potential risk of medication error, i.e., a child could receive a hepatitis immunization instead of a haemophilus vaccine booster dose at 15 months through 4 years of age, thereby decreasing the child’s continued Haemophilus protection.  Therefore, the risk of medication error is moderate.  We recommend that packaging for HIBERIX be distinct from Havrix to help mitigate the potential for confusion between these products.

Hexabrix and Imitrex have a similar sound like and look alike characteristic and are injectable products, however the dosage and administration schedule and indications are not similar to HIBERIX. Therefore the risk of medication error is low.  In addition, Hexabrix has a different storage condition than HIBERIX.  Hiprex has similar sound like and look alike characteristics with HIBERIX.  However, HIBERIX but does not have any overlapping product characteristics with Hiprex. Therefore, the risk of medication error is low.

In conclusion, HIBERIX has similar sound alike and look-alike characteristics and overlapping product characteristics with Havrix and therefore appears to be at risk for medications errors.

The Office of Biostatistics and Epidemiology/Division of Epidemiology/Vaccine Safety Branch provided VAERS reports of ActHIB and PedvaxHIB errors.  In the last 5 years, there have been 10 reports of Havrix, Comvax, Pneumovax, Infanrix, and Vaqta being administered instead of Pedvax HIB.  

Recommendations:

APLB recommends that the proposed proprietary name HIBERIX be found Acceptable with Concerns.  There is a potential risk that HIBERIX and Havrix may be mixed up, thereby causing medication errors. Therefore, we recommend that the HIBERIX packaging be sufficiently distinct from Havrix to avoid medication errors.

If OVRR accepts our recommendation that the proposed proprietary name HIBERIX be found acceptable with concerns, please include the following text in your letter to the manufacturer:

In consultation with CBER’s Advertising and Promotional Labeling Branch (APLB), we have considered your proposed proprietary name HIBERIX and conclude that under 21 CFR Part 201 the proposed proprietary name is acceptable with concerns.  There is a potential risk for medication errors with Havrix, however, these risks may be minimized by providing packaging that will differentiate HIBERIX from Havrix.

If you have any questions with regards to this review, please contact Maryann Gallagher, Consumer Safety Officer at 301-827-3028.

References: 

Firm name:      Glaxo Smithkline

 

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002